HomeComparePSTI vs MCD

PSTI vs MCD: Dividend Comparison 2026

PSTI yields 200.00% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSTI wins by $119.29M in total portfolio value
10 years
PSTI
PSTI
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full PSTI calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — PSTI vs MCD

📍 PSTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSTIMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSTI + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSTI pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSTI
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, PSTI beats the other by $51,127,388.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSTI + MCD for your $10,000?

PSTI: 50%MCD: 50%
100% MCD50/50100% PSTI
Portfolio after 10yr
$59.72M
Annual income
$30,101,161.99/yr
Blended yield
50.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

PSTI
Analyst Ratings
8
Buy
2
Hold
Consensus: Buy
Altman Z
-41.5
Piotroski
4/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSTI buys
0
MCD buys
0
No recent congressional trades found for PSTI or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSTIMCD
Forward yield200.00%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$119.36M$78.5K
Annual income after 10y$60,176,096.29$26,227.70
Total dividends collected$112.49M$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: PSTI vs MCD ($10,000, DRIP)

YearPSTI PortfolioPSTI Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$30,700$20,000.00$10,815$334.85+$19.9KPSTI
2$90,232$57,383.18$11,826$491.71+$78.4KPSTI
3$254,173$157,624.56$13,123$730.06+$241.1KPSTI
4$686,927$414,961.74$14,853$1,100.07+$672.1KPSTI
5$1,783,118$1,048,106.39$17,257$1,690.61+$1.77MPSTI
6$4,450,613$2,542,677.12$20,752$2,667.01+$4.43MPSTI
7$10,693,420$5,931,263.38$26,103$4,354.83+$10.67MPSTI
8$24,760,608$13,318,648.86$34,794$7,437.78+$24.73MPSTI
9$55,315,649$28,821,798.66$49,926$13,461.60+$55.27MPSTI
10$119,363,841$60,176,096.29$78,550$26,227.70+$119.29MPSTI

PSTI vs MCD: Complete Analysis 2026

PSTIStock

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Full PSTI Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this PSTI vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSTI vs SCHDPSTI vs JEPIPSTI vs OPSTI vs KOPSTI vs MAINPSTI vs YUMPSTI vs QSRPSTI vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.